TICKERNERD
Menu
BIIBBIIBHealthcare · Drug Manufacturers - General

BIIB Stock Forecast: Biogen, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$223
−0.31% on the day

The 35 Wall Street analysts covering Biogen, Inc. hold a median 12-month price target of $240 — +7.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 6 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$32.5B
Ticker Nerd rank
76 / 100
Median analyst target
$240
Analysts covering
35
Revenue$2.7B+3.4% y/y
Operating income$482.8M
Net income$97.5M
Free cash flow$308.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.8%
1M
+0.9%
YTD
+26.6%
1Y
+44.7%
From 52W high
−2.5%
From 52W low
+56.7%
$142
$229
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BIIB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Biogen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
76 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Volatility
96
Momentum
89
Quality
86
Accruals
62
Revisions
61
Growth
40
Issuance
32
Size
7

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (32): The company has been issuing shares or taking on financing, diluting existing holders.

Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BIIB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BIIB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250$300Jan 26Apr 26Jul 26Oct 26BIIBHigh $300Median $240Low $175

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says35 analysts
22 Buy12 Hold1 Sell
Low $175Median $240High $300

The green dot is the last close — the median target sits +7.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
10 Sept 2026HSBCMaintainsReduce$165 → $175
3 Sept 2026Piper SandlerReiteratesOverweight$225 → $245
25 Aug 2026RBC CapitalMaintainsOutperform—
25 Aug 2026RBC CapitalMaintainsOutperform$240 → $260
13 Aug 2026Wolfe ResearchUpgradeOutperform$300
13 Aug 2026Wolfe ResearchUpgradeOutperform—
4 Aug 2026MizuhoMaintainsOutperform—
4 Aug 2026MizuhoMaintainsOutperform$221 → $241
3 Aug 2026CitigroupMaintainsNeutral—
3 Aug 2026CitigroupMaintainsNeutral$200 → $215
30 July 2026Canaccord GenuityMaintainsBuy—
30 July 2026Canaccord GenuityMaintainsBuy$245 → $248
30 July 2026HC Wainwright & Co.MaintainsBuy$237 → $251
30 July 2026HC Wainwright & Co.MaintainsBuy—
30 July 2026Morgan StanleyMaintainsEqual-Weight$222 → $231
30 July 2026Morgan StanleyMaintainsEqual-Weight—
30 July 2026RBC CapitalMaintainsOutperform—
30 July 2026RBC CapitalMaintainsOutperform$242 → $240
30 July 2026TD CowenMaintainsBuy—
30 July 2026TD CowenMaintainsBuy$215 → $225

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BIIB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BIIB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Biogen, Inc. returned +44.7% against +17.3% for the S&P 500, dividends included.

BIIB vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Jan 26Apr 26Jul 26Oct 26BIIBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BIIB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−5.9%
Analysts raising
0
Analysts cutting
0
Fundamentals

Biogen, Inc. (BIIB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
39.1×

Cheaper than 19% of US stocks

Price / sales
3.2×

Cheaper than 38% of US stocks

Price / book
1.7×

Cheaper than 49% of US stocks

EV / EBITDA
11.8×

Cheaper than 31% of US stocks

Growth & margins
Revenue growth (YoY)
3.4%

Higher than 35% of US stocks

Earnings growth (YoY)
−84.6%

Higher than 4% of US stocks

Gross margin
71.6%

Higher than 84% of US stocks

Operating margin
25.1%

Higher than 84% of US stocks

Net margin
8.3%

Higher than 66% of US stocks

Returns & dividend
Return on equity
4.6%

Higher than 53% of US stocks

Return on assets
5.2%

Higher than 78% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Biogen, Inc. (BIIB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Biogen, Inc. has a market value of $32.5B and an enterprise value of $39.6B.

  • Revenue in the twelve months to 30 June 2026: $10.0B. The latest quarter grew 3.4% year on year.

  • Net income over the same four quarters: $834.6M, a 8.3% net margin.

  • Diluted earnings per share, trailing twelve months: $5.65.

  • Free cash flow in the twelve months to 30 June 2026: $2.5B.

  • Shares outstanding: 147.7M.

  • Trailing P/E: 39.1×; forward P/E: 13.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Biogen, Inc. employs 7,500 people — $1.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

BIIB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
BIIBBiogen, Inc.$32.5B
76
BMYBristol Myers Squibb Co.$121.3B
99
PFEPfizer Inc.$156.4B
82
GILDGilead Sciences, Inc.$179.1B
94
AMGNAmgen, Inc.$217.0B
93
OGNOrganon & Co.$3.6B
76
MRKMerck & Co., Inc.$352.3B
83

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Biogen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BIIB news & analysis

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter

CNBC Television · 6 Oct 2026neutral

Goldman Sachs lead U.S. biotech analyst Salveen Richter joined CNBC’s “Closing Bell Overtime” to discuss biotech innovations in China and noted that large biopharma companies are looking at Chinese assets.

Why it matters — The discussion concerns large biopharma companies’ interest in China assets, a topic relevant to BIIB watchers tracking the sector’s innovation landscape.

Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says

Proactive Investors · 6 Oct 2026positive

Jefferies expects Biogen to report third-quarter EPS of $2.14, slightly above the $2.07 consensus, with revenue in line at $2.6 billion. Lower cost of goods sold and R&D expenses are expected to be partly offset by higher selling, general and administrative costs.

Why it matters — BIIB watchers will be monitoring the October 28 report for whether earnings meet Jefferies’ estimate and revenue aligns with consensus.

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

Zacks Investment Research · 6 Oct 2026positive

Zacks Investment Research says Biogen has a strong history of earnings surprises and currently has two factors it views as supportive of a likely beat in its next quarterly report.

Why it matters — The item highlights expectations around whether Biogen will exceed estimates in its upcoming earnings report.

25 Stocks to Avoid as October Trading Gets Underway

Schaeffers Research · 6 Oct 2026neutral

Schaeffers Research highlighted 25 stocks to avoid amid early-October market volatility, citing swings in Treasury yields and crude prices and shifting sentiment after weaker-than-expected September payrolls. Investors are also looking ahead to the FOMC meeting and upcoming inflation and jobs data.

Why it matters — The excerpt does not identify Biogen among the 25 stocks, but it frames a period of broader market uncertainty that BIIB watchers may follow.

Biogen's experimental lupus drug shows benefit against skin symptoms

Reuters · 2 Oct 2026positive

Biogen announced that its experimental drug demonstrated durable improvement in skin symptoms among patients with a type of autoimmune disease, based on findings from a mid-stage study released on Friday.

Why it matters — The positive mid-stage result suggests progress for Biogen's experimental lupus treatment, which could be significant for the company's pipeline.

FAQ

Frequently asked questions about BIIB stock

What is the BIIB stock price forecast for 2026-2027?

The 35 Wall Street analysts covering Biogen, Inc. have a median 12-month price target of $240, with estimates ranging from $175 to $300. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BIIB stock a buy right now?

Of the 35 analysts covering Biogen, Inc., 22 rate it a Buy, 12 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Biogen, Inc. 76 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BIIB?

As at 6 Oct 2026, Biogen, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will BIIB stock go up?

No one can know that. What the data says: the median 12-month target from 35 analysts implies +7.7% from the last close, and Ticker Nerd's factor model ranks Biogen, Inc. 76 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BIIB stock forecast for 2030?

No analyst covering Biogen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BIIB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $175 to $300 over the next 12 months.

How has BIIB stock performed over the past year?

Biogen, Inc. returned +44.7% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Biogen, Inc. do?

Biogen Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for serious neurological, neurodegenerative, and rare diseases.

What is the latest news on BIIB?

The most recent item we track (CNBC Television, 6 Oct 2026): "Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter". Goldman Sachs lead U.S. biotech analyst Salveen Richter joined CNBC’s “Closing Bell Overtime” to discuss biotech innovations in China and noted that large biopharma companies are looking at Chinese assets.

Company

About Biogen, Inc.

Biogen Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for serious neurological, neurodegenerative, and rare diseases. Biogen’s current portfolio includes treatments for multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis, and Friedreich’s ataxia, along with therapies and biosimilars used in specialized immunology and related areas. The company also advances medicines through its research and development programs, with a strong emphasis on neuroscience and immunology. Based in Cambridge, Massachusetts, Biogen serves patients and healthcare providers across multiple global markets through its commercial products and collaborations. Its role in the financial market is shaped by its concentration in specialty biopharmaceuticals, recurring demand for chronic-disease treatments, and continued activity in pipeline development and product commercialization.

CEO Mr. Christopher A. Viehbacher · 7,500 employees · United States · https://www.biogen.com